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F U L M I N A N T H E P A T I T I S : A C L I N I C A L R E V I E W O F 11 Y E A R S 
Anna Sara Shafferman L E V I N , Antonio Alei B A R O N E & Mario S H I R O M A 
S U M M A R Y 
24 cases of fulminant hepatitis (FH) hospitalized in the Clínica de Doenças 
Infecciosas e Parasitárias do Hospital das Clínicas da Faculdade de Medicina da 
Universidade de São Paulo during the period from January 1976 to December 1986 
were reviewed from their clinical, epidemiological and laboratorial aspects. 
88% of the patients died; 20 patients (83%) presented hemorrhages and, of 
these, 19 died. Bacterial infections occurred in 14 patients (58%) all of whom died. 
Ascitis was noted in 3 cases; cerebral edema was present in 16 cases. 
Maximal A L T levels for each patient during hospitalization ranged widely from 
81 to 4,460 U I / Í . Thirteen patients presented high creatinine levels (54%). 
Prothrombin time activity ranged from 2.1% to 67%. Fever was present in 20 cases 
(83%). Encephalopathy occurred within the first 2 weeks of illness in 72% of the 
cases. In 7 cases other illnesses were present. 
The etiology could not be determined in 13 cases. In 3 cases it was due to yellow 
fever and 6 cases were caused by viruses other than yellow fever. In one case the 
cause was drug usage and in another case, possibly alcohol. 
The authors believe that the clinical definition of F H requires further discussion 
before it is established. In this study F H is a young person's disease. The mortality 
found was similar to that by other authors. Factors that contributed to death were: 
hemorrhages and bacterial infection. Factors that worsened the prognosis of 
hepatitis were: associated illnesses and surgical procedure. 
The levels of A L T during hospitalization did not correlate well with the severity 
of the hepatitis. 
The authors believe that yellow fever should be considered a cause of F H where 
the clinical picture meets the criteria for such, although its mechanisms of 
encephalopathy remain obscure. The clinical details of the 3 cases of yellow fever are 
presented. 
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I N T R O D U C T I O N 
Fulminant hepatitis (FH) is a rare clinical 
syndrome which results from a massive 
destruction of hepatocytes and which can be 
considered a sudden severe liver malfunction 
without a previously known hepatopathy1 7 1 8. 
It can be caused by various factors: virus, 
drugs (halothane, isoniazide, acetaminophen, 
alcohol), pregnancy, surgical shock, etc.1 8. 
The clinical definition of this syndrome is 
controversial; however the most accepted is 
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that of T R E Y 2 1 — an acute severe hepatitis that 
leads to a severe hepatic encephalopathy within 
the first 8 weeks of illness. 
Fulminant hepatitis is a highly lethal illness 
and its mortality varies according to different 
studies — 8 5 . 7 % " , 9 2 . 5 % 3 , 94% 1 * . Its 
prognosis is worsened by the following factors: 
pregnancy 9, undernourishment8-9, previous 
surgery i, old age1*. 
The object of this study is to demonstrate 
different aspects of F H in Braz i l — 
epidemiological, clinical and laboratorial. We 
believe this to be useful in view of the fact that 
very few studies have been made on this subject 
in our country. 
M E T H O D S 
Through the hospital's computerized 
registry system we made a survey of all the 
patients with diagnosis of hepatitis hospitalized 
in the Cl ín ica de Doenças Infecciosas e 
Parasitárias do Hospital das Clínicas da 
Faculdade de Medicina da Universidade de São 
Paulo, during the period from January 1976 to 
December 1986. Studying each of these cases 24 
patients presented the clinical picture of F H 
based on T R E Y ' s criteria21. From these reports 
we collected all the information available on 
epidemiology (age, sex, use of blood or blood 
products, previous contact with hepatitis), 
clinical data (time of illness until the onset of 
encephalopathy, fever, duration of encephalo-
pathy, complications, outcome), laboratorial 
data (aminotransferase levels, prothrombin 
time, kidney funct ion, bi l i rubin levels, 
serology), and hystological data (obtained 
through necropsy or biopsy). 
The serologic tests for antibodies against 
hepatitis A virus (enzyme-linked immuno-
absorbent assay) were incomplete as these tests 
were only initiated in 1985. A complete evalua-
tion of hepatitis B virus infection (through the 
enzyme-linked immunoabsorbent assay and the 
radioimmunoassay) began in 1985 and previous 
to this date only HBsAg and anti-HBs were 
studied through radioimmunoassay. Before 
1982 the only test used was complement 
fixation for the study of the Australia antigen. 
Necropsies were performed in 20 cases and 
in 1 case a biopsy only was obtained. It was 
possible to review these results in only 5 cases. 
The treatment given in all the cases of F H 
was supportive care as described by 
S H E R L O C K 1 8 . 
R E S U L T S 
Fourteen (58%) of the 24 patients with F H 
were male. Their distribution according to age 
can be seen in Figure 1 (mean age: 23 years). 
Twenty-one patients (88%) died. The 3 
survivors refused liver biopsy during follow-up 
as outpatients and presented a complete clinical 
cure. Sixty-eight percent of the patients who 
died did so during the first month of illness (95 
percent confidence interval: 48 to 88%). 
The mean duration of the illness until the 
onset of encephalopathy was 16 days (range: 4 
to 60 days) as can be seen in Figure 2. This 
information could be collected in 22 cases. 
The lowest prothrombin time activity 
measured for each patient ranged from 2.1% to 
67% of normal (mean: 17.38%). The highest 
creatinine level registered for each patient 
ranged from 0.5 to 14.7 mg/100 ml (mean: 4.3) 
and only 13 patients (54%) presented levels 
above 1.2 mg/100 ml. In these 13 cases the 
mean level was 6.42 mg/100 ml. 
The highest aminotransferase levels 
registered for each patient ranged from 81 to 
4,460 U l / i (mean: 1,524) for alanine 
aminotransferase ( A L T or S G T P ) — Figure 3; 
and from 53 to 6,800 U l / i (mean: 2,227) for 
aspartate aminotransferase (AST or SGOT) . 
A S T levels were retrieved in 22 cases. The upper 
A L T level was higher than the upper A S T 
level in 10 cases and in 6 of these the ratio 
A L T / A S T was above 1.5. The upper A S T level 
was higher than the upper A L T level in 12 cases 
and the ratio A S T / A L T was above 1.5 in 5 
cases. 
Fever was present in 20 cases (83%). 
Cerebral edema was present in 16 of the 21 
patients who died (76%). 
Hemorrhages occurred in 20 cases (83%) 
and of these the final outcome was fatal in 19 
(95%). Secondary bacterial infections were 
encountered in 14 patients (58%) and in all of 
these cases the final outcome was death. The 
site of these infections can be seen in Figure 4. 
Ascitis w^s noted in 3 of the 21 patients 
who died (14%). 
In 7 fatal cases there were other illnesses 
concomitant with F H : neurocisticercosis, 
NUMBER OF PATIENTS 
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F i g . 1 — Distribution of patients according to age 
carcinoma of the esophagus, chronic 
pancreatitis, hemophilia A , perforation of a 
duodenal ulcer on the day before death (this 
patient underwent surgery on this same day), 
pleural tuberculosis, and Hodgkin's lymphoma 
under chemotherapy. 
The mean time of hospitalization among 
the patients who died was 11 days (range: 1 to 
53); and the mean time among the 3 survivors 
was 22 days (11, 25 and 28 days respectively). 
There is insufficient data to determine the 
etiology of all the cases. Three cases were 
caused by the yellow fever virus and 6 cases 
were attributed to other viruses (25%). Of these 
6 cases one was caused by hepatitis A virus (this 
patient survived), 2 cases were caused by 
hepatitis B virus, and 3 cases were attributed to 
viruses (probably B virus) based on necropsy 
results and incomplete serologic data. The 
serology for antibodies against hepatitis A virus 
was performed in only 6 cases. 
In one case, where F H was due to hepatitis 
B virus, the patient also had Hodgkin's 
l y m p h o m a and had been rece iv ing 
chemotherapy (vincristine, cyclophosphamide, 
prednisone and procarbazine) up to 20 days 
before the onset of the hepatitis. This patient 
died on the 8 t h day of the disease and on the 2 n d 
day of encephalopathy. Another patient who 
'had viral hepatitis took a hepatotoxic drug 
regularly (isoniazide). 
In one case the cause was drug usage and 
this patient took carbamazepine, phenobarbital 
and diazepan regularly. In one case the possible 
cause of F H was alcohol abuse. 
The data of the 3 cases caused by yellow 
fever can be seen on Table 1. Al l these patients 
had been on recent trips to areas of Brazil 
where this disease is endemic (Mato Grosso and 
Mato Grosso do Sul). 
In 13 cases the cause of the hepatitis could 
not be clearly defined: one patient presented 
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F i g . 2 — Durat ion of illness until the onset of encephalopathy 
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T A B L E 2 
E t i o l ogy o f the cases 
Case E t i o l ogy Ou tcome Other Cond i t ions 
01 a lcohol death chronic pancreati t is 
02 u n k n o w n death carc inoma of the esophagus 
03 v i r a l * death Hodgk in ' s l ymphoma , 
chemotherapy 
04 u n k n o w n death -
05 unknown death hemophi l ia A , a lcohol ism 
06 u n k n o w n death -
07 v i r a l * death _ 
08 drug death -
09 u n k n o w n death -
10 ye l low fever death a lcohol ism 
11 ye l low fever death -
12 u n k n o w n survival a lcohol ism 
13 u n k n o w n death neurocist icercosis, 
praz iquante l , dexamethasone 
14 unknown death a lcohol ism 
15 u n k n o w n death a lcohol ism 
16 v i rus B death 
17 v i r a l * death pleural tuberculosis, 
isoniazide 
18 u n k n o w n death -
19 ye l low fever death -
20 v i rus A survival -
21 v i rus B survival -
22 unknown death -
23 unknown death a lcohol ism 
24 unknown death isoniazide, 
surgery for a perforated ulcer 
( * ) Cases attr ibuted to viruses based on necropsy results and incomplete serologic data. 
HBsAg in the serum and 2 were positive for 
anti-HBs; 5 drank alcohol regularly; one took 
isoniazide regularly; and one patient had 
undergone treatment for neurocisticercosis with 
dexamethasone and praziquantel. 
The results of the necropsy and biopsy 
studies were: acute alcoholic hepatitis in one 
case; massive liver necrosis in 9 cases; 
submassive liver necrosis in 5 cases; acute 
hepatitis in 3 cases; yellow fever in 3 cases. 
D I S C U S S I O N 
There are different accepted definitions of 
F H although the most used is that oi' T R E Y 2 1 
which includes all acute cases of hepatitis that 
lead to severe hepatic encephalopathy within 
the first 8 weeks of illness (with a presumed 
normal liver function prior to the disease). 
Other authors believe that the period concerned 
should be shorter: 4 weeks 1 0 1 1 . In our study 
72% of the patients presented encephalopathy 
during the first 2 weeks of illness (95 percent 
confidence interval: 54 to 90%). We believe this 
matter deserves a great deal more discussion 
before it is established. 
In our study 75% of the patients were 
under 30 years of age (95 confidence interval: 
59 to 91%). This would indicate that in our 
environment F H is a young person's disease, 
contrary to what has been reported in some 
other studies 9 ' 1 1 1 6. 
Mortality in our study was 88% similar to 
results obtained in other s tud ies 3 1 6 2 3 . Our 
findings are also similar to those of other 
reports where illnesses concomitant with F H 
worsened the outcome. Factors that could 
contribute to death are: hemorrhages, cerebral 
edema, secondary bacterial infections, renal 
failure, pancreatitis, pulmonary and circulatory 
failure 5 8. A l l our patients who presented 
secondary bacterial infections died (14 cases) 
and only one of the 20 patients who presented 
hemorrhages survived. In 7 patients there were 
other illnesses associated with F H , and in all 
these cases the final outcome was fatal. 
There have been reports of cancer patients 
treated with chemotherapy who presented F H 
caused by the hepatitis B virus (HBV) after 
withdrawl of immunossupression1 6 1 9-2 2. One of 
our patients had Hodgkin's lymphoma which 
was treated with chemotherapy until 20 days 
before the onset of F H (positive for Australia 
antigen). Another patient had received 
dexamethasone over a long period (1.5 months) 
during treatment for neurocisticercosis and 
received also praziquantel before presenting 
F H . It was not possible to determine the 
etiology of this hepatitis. 
Another factor which could negatively 
affect the prognosis of hepatitis is surgical 
procedure. This event occurred in one of our 
cases where a patient with hepatitis was 
submited to emergency surgery for a perforated 
gastric ulcer. The following day the patient 
presented hepatic encephalopathy and died. 
It is difficult to establish the influence of 
hepatotoxic drugs in worsening the outcome of 
the disease when these are associated with viral 
hepatitis2. In one of our cases of F H this 
association was present (the patient took 
isoniazide regularly). 
Although a complete follow-up of the 
survivors was not possible, they presented a 
clinical cure. We believe that the majority of 
the survivors of F H will have a complete cure 5 1 3 
and only rarely will chronic hepatitis develop. 
In our study ascitis was present in 3 of the 
21 patients who died. L E B R E C et à l . 6 described 
a high occurrence of ascitis in F H , as opposed 
to what occurs in other forms of acute viral 
hepatitis. This could be explained by the 
presence of portal hypertension and by the 
sodium retention that occurs in F H . Our 
f indings are similar to those of other 
authors5-16. 
Fifty percent of our patients presented very 
high alanine aminotransferase ( A L T ) levels 
(above 1,500 U l / i ) during hospitalization (95 
percent confidence interval: 30 to 70%). Thus it 
is not possible to assert that the A L T values 
obtained during hospitalization correlate to the 
severity of the hepatitis. The upper A S T level 
for each patient varied widely in relation to the 
upper A L T level and no trend could be 
determined. 
The etiology of F H in our cases was made 
difficult to determine by the absence of 
serologic data. It is important however to 
remember the possibility of an increase in the 
severity of hepatitis when more than one virus 
is involved 7 1 4 1 5 ' 2 0 . In our cases nothing could be 
substantiated in this respect. 
Our three yellow fever cases were 
considered F H because they met the clinical 
criteria for such. In yellow fever the 
physiopathological mechanisms of 
encephalopathy are unknown. Many factors 
may play a role: hipotension, acidosis, 
hypogl icemia, altered concentrations of 
aminoacids and neurotransmitters 1 2 . In 
experimental studies the virus was not found to 
invade the brain. These three patients had 
visited areas of Brazil where yellow fever is 
endemic (Mato Grosso and Mato Grosso do 
Sul) and had contact with the forest. This 
transmission of yellow fever should be 
considered 'sy lvat ic ' (monkey-mosquito-
human) and not 'urban' (interhuman). 
In all three cases complications developed 
that probably worsened the prognosis and 
could be related to their fatal outcome: severe 
hemorrhages, renal failure, coma, very high 
levels of serum aminotransferase12. The definite 
diagnosis was made through necropsy and 
hystopathologic examination of the liver. 
R E S U M O 
Hepatite fulminante: uma retrospectiva clínica 
de 11 anos 
Vinte e quatro casos de hepatite fulminan-
te (HF) , internados na Clínica de Doenças In-
fecciosas e Parasitárias do Hospital das Clíni-
cas da Faculdade de Medicina da Universidade 
de São Paulo durante o período de janeiro de 
1976 a dezembro de 1986, foram revistos para a 
obtenção de dados clínicos, epidemiológicos e 
laboratoriais. 
88% dos pacientes morreram. Vinte (83%) 
dos pacientes apresentaram hemorragias, den-
tre os quais 19 morreram (95%). Infecções bac-
terianas secundárias ocorreram em 14 pacientes 
(58%) todos os quais faleceram. Ascite foi no-
tada em 3 casos e edema cerebral em 16 casos. 
Os valorec máximos de A L T obtidos para cada 
paciente durante a internação variaram de 81 a 
4.460 VI/i. Treze pacientes tiveram elevação 
de creatinina (54%). A atividade do tempo de 
protrombina variou de 2,1% a 67%. A febre es-
teve presente em 20 casos (83%). A encefalopa-
tia surgiu durante as 2 primeiras semanas de 
doenças em 72% dos casos. Em 7 casos havia 
doenças associadas à hepatite. 
A etiologia não pode ser determinada em 
13 casos; 3 casos foram por febre amarela; e 6 
casos por outros vírus. Em 1 caso a causa foi 
drogas e em um caso, possivelmente, foi álcool. 
Os autores acreditam que a definição de 
H F merece discussão antes de ser totalmente 
aceita. Neste estudo, a H F foi uma doença que 
acometeu principalmente jovens. A letalidade 
encontrada foi semelhante a de outros estudos. 
Fatores que contribuíram para o óbito foram 
hemorragias e infecções bacterianas secundá-
rias. Fatores de piora do prognóstico da hepati-
te foram a presença de outras doenças associa-
das e de procedimento cirúrgico. 
Os níveis de A L T durante a internação não 
refletiram a gravidade da hepatite. 
Os autores acreditam que a febre amarela 
deve ser considerada um agente etiológico de 
H F quando o seu quadro clínico seja compatí-
vel com tal, embora os mecanismos fisiopato-
lógicos da encefalopatia sejam ainda obscuros. 
Os dados clínicos dos 3 casos de febre amarela 
são apresentados à parte. 
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